» Articles » PMID: 34798911

α-Synuclein-mediated Neurodegeneration in Dementia with Lewy Bodies: the Pathobiology of a Paradox

Overview
Journal Cell Biosci
Publisher Biomed Central
Specialty Biology
Date 2021 Nov 20
PMID 34798911
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Dementia with Lewy bodies (DLB) is epitomized by the pathognomonic manifestation of α-synuclein-laden Lewy bodies within selectively vulnerable neurons in the brain. By virtue of prion-like inheritance, the α-synuclein protein inexorably undergoes extensive conformational metamorphoses and culminate in the form of fibrillar polymorphs, instigating calamitous damage to the brain's neuropsychological networks. This epiphenomenon is nebulous, however, by lingering uncertainty over the quasi "pathogenic" behavior of α-synuclein conformers in DLB pathobiology. Despite numerous attempts, a monolithic "α-synuclein" paradigm that is able to untangle the enigma enshrouding the clinicopathological spectrum of DLB has failed to emanate. In this article, we review conceptual frameworks of α-synuclein dependent cell-autonomous and non-autonomous mechanisms that are likely to facilitate the transneuronal spread of degeneration through the neuraxis. In particular, we describe how the progressive demise of susceptible neurons may evolve from cellular derangements perpetrated by α-synuclein misfolding and aggregation. Where pertinent, we show how these bona fide mechanisms may mutually accentuate α-synuclein-mediated neurodegeneration in the DLB brain.

Citing Articles

Advancements in PROTAC-based therapies for neurodegenerative diseases.

Kong D, Meng L, Lin P, Wu G Future Med Chem. 2025; 17(5):591-605.

PMID: 39931801 PMC: 11901405. DOI: 10.1080/17568919.2025.2463310.


Protective Effects of Ambroxol on Aβ and α-Synuclein-Induced Neurotoxicity Through Glucocerebrosidase Activation in HT-22 Hippocampal Neuronal Cells.

Lin S, Chang C, Tsou S, Chiu P, Cheng J, Hung H Int J Mol Sci. 2024; 25(22).

PMID: 39596182 PMC: 11593818. DOI: 10.3390/ijms252212114.


Targeted protein degradation: advances in drug discovery and clinical practice.

Zhong G, Chang X, Xie W, Zhou X Signal Transduct Target Ther. 2024; 9(1):308.

PMID: 39500878 PMC: 11539257. DOI: 10.1038/s41392-024-02004-x.


Modeling Lewy body disease with triplication iPSC-derived cortical organoids and identifying therapeutic drugs.

Jin Y, Li F, Li Z, Ikezu T, OLeary J, Selvaraj M Sci Adv. 2024; 10(37):eadk3700.

PMID: 39259788 PMC: 11389790. DOI: 10.1126/sciadv.adk3700.


Unlocking the Potential: Semaglutide's Impact on Alzheimer's and Parkinson's Disease in Animal Models.

Meca A, Boboc I, Mititelu-Tartau L, Bogdan M Curr Issues Mol Biol. 2024; 46(6):5929-5949.

PMID: 38921025 PMC: 11202139. DOI: 10.3390/cimb46060354.


References
1.
Kosaka K, OYANAGI S, Matsushita M, Hori A . Presenile dementia with Alzheimer-, Pick- and Lewy-body changes. Acta Neuropathol. 1976; 36(3):221-33. DOI: 10.1007/BF00685366. View

2.
McKeith I, Boeve B, Dickson D, Halliday G, Taylor J, Weintraub D . Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017; 89(1):88-100. PMC: 5496518. DOI: 10.1212/WNL.0000000000004058. View

3.
Polymeropoulos M, Lavedan C, Leroy E, Ide S, Dehejia A, Dutra A . Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997; 276(5321):2045-7. DOI: 10.1126/science.276.5321.2045. View

4.
Mahul-Mellier A, Burtscher J, Maharjan N, Weerens L, Croisier M, Kuttler F . The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc Natl Acad Sci U S A. 2020; 117(9):4971-4982. PMC: 7060668. DOI: 10.1073/pnas.1913904117. View

5.
Khachaturian Z . Diagnosis of Alzheimer's disease. Arch Neurol. 1985; 42(11):1097-105. DOI: 10.1001/archneur.1985.04060100083029. View